The promising outcomes from studies of the radioligand lutetium Lu 177 vipivotide tetraxetan (Lu177-PSMA) as a second-line therapy for metastatic castration-resistant prostate cancer (mCRPC) has encouraged researchers to explore its effectiveness when moved earlier in treatment and in combination with other cancer therapies.
The issue of metastasis in prostate cancer can’t really be discussed without a startling fact: Black men are disproportionately affected by prostate cancer (PCa), with earlier presentation, more aggressive disease, and higher mortality rates vs. white men.
The U.S. government and the VA increasingly recognize the increased risk of prostate cancer faced by veterans and its relationship to service in areas of conflict.
Since receiving Food and Drug Administration (FDA) approval in 2022 for use in metastatic castration-resistant prostate cancer (mCRPC), adoption of lutetium Lu 177 vipivotide tetraxetan (Lu177-PSMA) has grown rapidly.
As the options for treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to increase, determining the best order for sequencing them becomes more complicated.
